There's little doubt now -- study after study, in real life and in lab dishes, in the US and elsewhere -- that people's immunity starts to wane just months after they finish the two-dose series of ...

Novo Nordisk’s CEO dared Pfizer to bid more if it wanted obesity drug developer Metsera so badly. So Pfizer did, with a $10 billion bid that edges out what the Danish pharmaceutical giant was willing ...